Targets › CA16
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Nov 2026.
Open in Phaseline: the race on CA16, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sinovac Biotech | bivalent enterovirus vaccine (Vero cell), inactivated inactivated bivalent enterovirus vaccine targeting Enterovirus 71 and Coxsackievirus A16 | EV71, CA16 | Phase 3 | Hand, Foot, and Mouth Disease(HFMD) | Nov 2026 |
Hand, Foot, and Mouth Disease(HFMD) (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.